Abstract
A 49-year-old white man with blood group AB, D+ was found to have alloanti-Jka and -K when he developed a delayed hemolytic transfusion reaction before allogeneic hematopoietic stem cell transplant (HSCT). Given that his stem cell donor was blood group O, D+, Jk(a+), K-, rituximab was added to his conditioning regimen of fludarabine and melphalan to prevent hemolysis of engrafting Jk(a+) donor red blood cells. The patient proceeded to receive a peripheral blood stem cell transplant from a matched unrelated donor with no adverse events. To our knowledge, this is the first case of successful management of major non-ABO incompatibility caused by anti-Jka in a patient receiving an allogeneic HSCT reported in the literature.
Original language | English |
---|---|
Pages (from-to) | 11-14 |
Number of pages | 4 |
Journal | Immunohematology |
Volume | 29 |
Issue number | 1 |
DOIs | |
State | Published - 2013 |
Keywords
- Anti-Jk
- Hematopoietic stem cell transplantation
- Major incompatibility